Sepsis induced coagulopathy score and D-dimer levels in COVID-19 patients followed in intensive care; what has changed in COVID era?

Abstract

Aim: This study was planned to compare the extent of hypercoagulopathic complications in COVID-19 pneumonia with that of last year's pneumonia cases which consist of by other agents. Material and Method: The data of patients with pneumosepsis due to non-COVID-19 causes between 01 April-30 June 2019 and COVID-19 pneumosepsis patients between 01 April-30 June 2020,were analyzed retrospectively. Demographic data, comorbidities, SOFA scores, SIC scores, D-dimer levels, coagulopathic complications, mortality and discharge status of patients diagnosed with pneumosepsis and treated in both periods were recorded Results: While sequential D-dimer measurements did not show a significant change in the 2019 group, it was observed that it increased significantly in the 2020 group (p<0.05). When we analyse the coagulopathic complications,we saw that submassive pulmonary embolism was recorded in one patient in the 2019 group.In the 2020 group, one patient had disseminated intravascular coagulation (DIC) and one patient had massive pulmonary embolism. Conclusion: In our study, we did not find a significant difference in SIC scores and mortality rates between pneumosepsis patients in last years and COVID-19 pneumosepsis patients.

Keywords

• COVID-19
• sepsis induced coagulopathy
• D-Dimer levels

References

1. Renu K, Prasanna PL, Valsala Gopalakrishnan A. Coronaviruses pathogenesis, comorbidities and multi-organ damage – a review. Life Sci 2020; 15; 255: 117839.
2. Gavriatopoulou M, Korompoki E, Fotiou D et al. Organ-specific manifestations of COVID-19 infection. Clin Exp Med 2020; 4: 493-506.
3. Boccia M, Aronne L, Celia B et al. COVID-19 and coagulative axis: review of emerging aspects in a novel disease. Monaldi Arch Chest Dis 2020; 90; 2: 271-6.
4. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020; 4; 135, 23 : 2033-40.
5. Yıldırım Ö, Bayram M, Özmen RS, et al. Evaluation of hematological indices in terms of COVID-19 related mortality and ICU admission. J Health Sci Med 2021; 4: 5: 666-670.
6. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care 2020; 18; 24, 1 : 360: 1-8.
7. Iba T, Nisio MD, Levy JH, Kitamura N, Thachil J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open 2017; 27: e017046: 1-7.
8. Tekyol D, Hökenek NM. Comparison of the ability of the shock index, modified shock index and age shock index to predict mortality in geriatric patients with COVID-19 pneumonia. J Health Sci Med 2021; 4: 5: 634-8.

9. Iba T, Levy JH, Warkentin TE, Thachil J, van der Poll T, Levi M. Scientific and Standardization Committee on DIC, and the Scientific and Standardization Committee on Perioperative and Critical Care of the International Society on Thrombosis and Haemostasis. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost 2019; 17: 1989-94.
10. Carsana L, Sonzogni A, Nasr A et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis 2020; 20: 1135-40.
11. Menter T, Haslbauer JD, Nienhold R, et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology 2020; 77: 198-209.
12. Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med 2020; 18; 173: 268-77.
13. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-62.
14. Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm Res 2020; 12: 1181-9.
15. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061-9
16. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 5: 1094-9.
17. Rico-Mesa JS, Rosas D, Ahmadian-Tehrani A, White A, Anderson AS, Chilton R. The role of anticoagulation in COVID-19-induced hypercoagulability. Curr Cardiol Rep 2020; 22: 1-6.
18. Iba T, Levy JH, Raj A, Warkentin TE. Advance in the management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Clin Med 2019; 8: 1-16.
19. Schmitt FCF, Manolov V, Morgenstern J et al. Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Ann Intensive Care 2019; 9: 1-15.
20. Inata Y. Should we treat sepsis-induced DIC with anticoagulants? J Intensive Care 2020; 18: 1-3.